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Abstract  
BACKGROUND: Acoustic radiation force impulse (ARFI) evaluates liver stiffness non-invasively 
and was invented recently. This technique can easily and accurately assess the degree of liver 
fibrosis in clinical practice.  
AIM: The aim of this study was to detect the diagnostic performance of ARFI elastography in the 
staging of fibrosis in some Egyptian patients with chronic HCV infection.  
PATIENTS AND METHODS: One hundred ninety patients with chronic HCV infection; 142 men 
and 48 women were enrolled in the study. They underwent liver biopsy examination for liver fibrosis 
detection. All demographic; clinical and biochemical data were recoded. ARFI examination was 
done for all subjects to detect liver stiffness measurement in relation to liver fibrosis detected by 
pathological examination of liver biopsies.  
RESULTS: Medians of liver stiffness measurement by shear wave velocity showed a significant 
increase as a grade of liver fibrosis increases (p ≤ 0.0001, highly significant). Liver stiffness was 
directly correlated to age, AST; ALT; INR and liver steatosis (p values were: 0.009; 0.0001; 0.013; 
0.006 and 0.04 respectively, significant). On the other hand, liver stiffness was inversely correlated 
to albumin; prothrombin concentration and platelets (p values were: 0.0001; 0.001, and 0.0001, 
respectively, significant). We found that shear wave velocity can predict F1; F2; F3 and F4 at cut-off 
values: 1.22; 1.32; 1.44 and 1.8 respectively. 
CONCLUSION: ARFI is a diagnostic noninvasive promising technique for liver fibrosis diagnosis 
among Egyptian patients with chronic HCV infection. 
 
 
 
Introduction 
 
The incidence of chronic hepatitis C has been 
increasing gradually and is a potentially life-
threatening problem especially among Egyptians. 
Sustained and repeated inflammatory stimuli can 
cause a stress repair response in the body, leading to 
the accumulation of a large number of extracellular 
matrixes in the liver tissue, leading to fibrosis [1]. 
Progression of fibrosis can cause cirrhosis or even 
liver cancer. Therefore, early detection is important for 
the prevention and control of liver fibrosis and 
cirrhosis. Liver biopsy is the main diagnostic method 
for liver fibrosis. However, it is an invasive method 
and associated complications limit its safety [2]. 
Recently, various non-invasive techniques for 
liver fibrosis assessment have been developed, 
including serum biomarkers and elastography 
techniques. Transient elastography (TE), real-time 
elastography (RTE), acoustic radiation force impulse 
imaging (ARFI) are the most frequent elastography 
techniques [3, 4]. 
ARFI evaluates liver stiffness non-invasively 
and was invented recently. This technique can easily 
and accurately assess the degree of liver fibrosis in 
clinical practice [5-7]. Fierbinteanu-Braticevici et al [8] 
reported that ARFI elastography showed very good 
accuracy in assessing all stages of liver fibrosis. In 
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addition, a meta-analysis by Nierhoff et al [9] also 
demonstrated good diagnostic accuracy. 
Nowadays, early and continuous detection of 
liver fibrosis has become increasingly important in 
order to make therapeutic decisions, determine 
prognosis and to follow-up disease progression. 
Hepatic fibrogenesis is a dynamic process reflecting 
an imbalanced extracellular matrix turnover. 
Evaluating the evolution of fibrosis over time can be 
therefore more important than a “once only” diagnosis. 
Recent evidence suggesting that liver fibrosis can be 
reversible [10, 11], further emphasizes the importance 
to monitor fibrosis over time, other than simply 
diagnosing its presence and staging its severity. 
Accurate, reproducible and easily applied methods 
are therefore required for the assessment of hepatic 
fibrosis 
The aim of this study was to detect the 
diagnostic performance of ARFI elastography in the 
staging of fibrosis in some Egyptian patients with 
chronic HCV infection. 
 
 
Patients and Methods 
 
Patients 
The study was conducted on 190 patients 
with chronic HCV infection; 142 men and 48 women 
with documented chronic HCV infection, recruited 
from Agouza Liver Center and National Research 
Center, Cairo. Chronic HCV diagnosis was based on 
elevated serum transaminase levels for at least six 
months and positive HCV antibody by the second-
generation enzyme-linked immunosorbent assay and 
confirmed by detection of circulating HCV RNA using 
polymerase chain reaction (PCR). A liver biopsy 
specimen was taken from every patient. The current 
study was approved by ethical committee in the 
national research center. An informed consent was 
signed by every patient before enrollment in the study. 
Demographic data; clinical data; biochemical 
investigations; results of abdominal ultrasonography; 
histopathological examination of liver biopsies and 
data of ARFI examination were recoded for every 
enrolled patient. 
We excluded any patients with history renal 
disorder, the recent history of cardiovascular disease 
or patients with hepatitis B infection or human 
immunodeficiency virus infection, autoimmune or 
metabolic liver diseases; abnormal coagulation 
profiles that preclude liver biopsies; international 
normalized ratio (INR) > 1.5, prothrombin time > 50 
seconds and platelet count < 50,000/mL. Relative and 
absolute contraindications to liver biopsy, e.g. biliary 
ductal dilatation, ascites, and the presence of 
hepatocellular carcinoma were also excluded. 
Histopathological Examination of Liver 
Biopsies 
Ultrasound-guided percutaneous liver biopsy 
specimens were taken from the patients and 
examined by two different pathologists , experienced 
in liver histology, who were unaware of the laboratory 
results or clinical diagnosis. Only specimens with the 
inter-observer agreement of stage of hepatic fibrosis 
were included in the study. METAVIR scoring system 
was used for staging hepatic fibrosis. Every biopsy 
specimen was staged on a scale of F0 to F4 (F0 = no 
fibrosis, F1 = portal fibrosis without septa, F2 = few 
septa, F3 = numerous septa without cirrhosis, and F4 
= cirrhosis) [12, 13]. 
 
Acoustic radiation force impulse 
elastography 
Acoustic radiation force impulse elastography 
was performed for all subjects within two months of 
the date of liver biopsy with a Siemens Acuson S3000 
Virtual Touch ultrasound system (Siemens AG, 
Erlangen, Germany) with a 6CI transducer. The 
principle underlying ARFI elastography is that sharing 
of the examined tissue induces a strain in the tissues. 
An acoustic ‘‘push’’ pulse is automatically produced by 
the ultrasound probe and directed to the side of a 
region of interest (ROI), which is where the speed of 
the shear wave is measured. This ROI has a 
predefined size, provided by the system (10 mm long 
and 5 mm wide).  
 
Figure 1: Ultrasonographic picture of  ARFI  examination for liver 
fibrosis 
 
The acoustic ‘‘push’’ pulse generates shear 
waves that propagate into the tissue, perpendicular to 
the ‘‘push’’ axis. Detection waves are also generated 
by the transducer to measure the propagation speed 
of these shear waves, which increases with fibrosis 
severity [14]. The speed of the shear waves, 
measured in meters per second, as well as 
measurement depth, is displayed by the system. For 
each patient, 10 valid ARFI measurements were 
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performed under fasting conditions, with the patient in 
supine position with the right arm in maximum 
abduction, by the intercostal approach in the right liver 
lobe, 1–2 cm under the liver capsule. Minimal 
scanning pressure was applied by the operator; the 
patient was asked to stop normal breathing for a 
moment to minimize breathing motion. The mean of 8-
10 valid measurements was calculated and 
considered indicative of the severity of fibrosis (Fig. 1, 
Fig. 2). The operators were blinded to any clinical or 
elastographic data. 
 
Figure 2: Output report of ARFI examination wit means, median and 
standard deviation 
 
Statistical analysis 
Data are expressed as median or mean ± SD 
or median and range where appropriate. Categorical 
data are described as the frequency of the subjects 
with a specific characteristic. Chi-square test or 
Fisher’s exact test was used for comparing categorical 
data and Student’s t-test, Mann-Whitney-U-test, or 
Kruskal-Wallis test, when appropriate, was used for 
comparing continuous variables. The sensitivity-to-
specificity relationship of each noninvasive diagnostic 
test was assessed by using receiver operating 
characteristic curves. Area under the receiver 
operating characteristic curve and the 95% confidence 
interval were calculated for detection of histologic 
fibrosis stage 2 or higher disease (F ≥ 2), detection of 
histologic fibrosis stage 3 or higher disease (F ≥ 3), 
and detection of cirrhosis (F4) in the entire study 
population. P ≤ .05 was considered indicative of a 
significant difference. Statistical analysis was 
performed using SPSS software version 12.0 (SPSS 
Inc., Chicago, IL, USA). 
 
Results 
 
Base line features of the studied patients 
were present in Table 1. One hundred ninety patients 
with chronic HCV infection who underwent liver 
biopsies for pathological examination were enrolled in 
the current study from May 2014 to May 2015. They 
were 142 men and 48 women with mean age of 53.74 
± 12.05.  
Table 1: Patients’ characteristics 
Variables   
HCV patients 
N = 190 
Age in years                    Mean ± SD 53.74 ± 12.05 
Sex 
       Male     No (%) 
       Female  No (%) 
 
142 (74.7) 
    48  (25.3 ) 
PH of Schisto: 
         Negative No (%) 
          Positive   No (%) 
 
  63 (33.2) 
127 (66.8) 
Viral load    IU/mL             Median (range)      114000 (0- 33400000) 
AST    IU/L                        Median (range)      44.50 (1.97-283) 
ALT   IU/L                         Median (range) 38.00 (8.00-270) 
Albumin gm/dl                  Median (range) 3.90 (1.40-4.01) 
Total bilirubin  mg/dl        Median (range) 1.20 (0.20-4.5) 
Direct  bilirubin  mg/dl      Median (range) 0.50 (0.00-3.9) 
P C %                               Median (range) 79.00 (31-199) 
INR                                   Median (range) 1.20 (0.8-3.9) 
GGT      IU/L                     Median (range) 31.00 (1.3-271) 
Platelets  ×10
3
                  Median (range) 130.50 (0.95-512.00) 
AFP    ng/ml                     Median (range) 6.50 (0.20-7900) 
CHOL    mg/dl                   Mean ± SD   167.69 ± 40.36 
TRG       mg/dl                  Mean ± SD   114.85 ± 39.30 
Histopathological examination 
         Steatosis %   median(range) 
 
         Fibrosis :     
                 F 1        No (%) 
                 F 2        No (%) 
                 F 3        No (%) 
                 F 4        No (%) 
Activity: 
 
                A 0         No (%) 
                A 1         No (%) 
                A 2         No (%) 
                A 3         No (%) 
  
 
    9 (4-17) 
 
 
  25 (13.2) 
  28 (14.7) 
 29 (15.3) 
108 (56.8) 
 
 
  8 (4.2) 
  64 (33.7) 
100 (52.7) 
18 (9.4) 
PH of Schisto: past history of Schistosomiasis; AST: aspartate transaminase; ALT: alanine 
transaminase; PC%: prothrombin concentration; INR: international normalized ratio; GGT: 
Gamma-glutamyl transpeptidase; AFP: α-fetoprotein; CHOL: cholesterol; TRG: 
triglycerides. 
 
The frequency of past history of 
Schistosomiasis was 66.8%. Histopathological 
examination of liver biopsies revealed that distribution 
of liver fibrosis grades: F1; F2; F3; F4 was 13.2%; 
14.7%; 15.3% and 56.8% respectively. Medians of 
liver stiffness measurement by sheer wave velocity 
showed a significant gradual increase as a grade of 
liver fibrosis increases (p ≤ 0.0001, highly significant) 
as shown in Table 2 and Fig. 3.  
Table 2: Distribution of liver stiffness measurements by ARFI 
among different grades of liver fibrosis 
Grades of 
fibrosis 
Shear wave 
velocity m/sec 
Median 
Shear wave 
velocity m/sec 
Range 
Χ
2
 P value 
F1 1.20 1.10 - 1.40 
26.460 0.0001⃰ 
F2 1.43 1.26 - 1.62 
F3 1.90 1.43 - 2.80 
F4 2.70 1.52 - 3.90 
⃰ : p is highly significant. 
 
Analyzing correlation of liver stiffness 
measurement by shear wave velocity to the studied 
parameters revealed that liver stiffness was directly 
correlated to age, AST; ALT; INR and liver steatosis 
(p values were: 0.009; 0.0001; 0.013; 0.006 and 0.04 
respectively, significant).  
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Figure 3: Box Plot diagram for distribution of liver stiffness 
measurement by ARFI among different grades of liver fibrosis 
 
On the other hand, liver stiffness was 
inversely correlated to albumin; prothrombin 
concentration and platelets (p values were: 0.0001; 
0.001 and 0.0001, respectively, significant) as shown 
in Table 3.  
Table 3: Correlation of liver stiffness measurements by ARFI 
with different studied variables among the studied patients 
Variables Correlation Coefficient 
R 
Coefficient of 
determination 
R2. 
P value 
Age  0.175** 0.031 0.009 
AST 0.295** 0.087 0.000 
ALT 0.165* 0.027 0.013 
Albumin -0.329** 0.108 0.000 
Total bilirubin 0.127 0.016 0.057 
Direct  bilirubin 0.062 0.004 0.354 
P C -0.224** 0.050 0.001 
INR 0.183** 0.033 0.006 
GGT 0.036 0.001 0.593 
Platelets -0.300** 0.09 0.000 
Viral load -0.036- 0.001 0.596 
AFP 0.110 0.012 0.099 
CHOL -0.086 0.007 0.200 
TRG -0.089 0.008 0.186 
Liver steatosis  0.141* 0.020 0.042 
AST: aspartate transaminase; ALT: alanine transaminase; PC%: prothrombin 
concentration; INR: international normalized ratio; GGT: Gamma-glutamyl transpeptidase; 
AFP: α-fetoprotein; CHOL: cholesterol; TRG: triglycerides; ⃰: p is significant; ⃰⃰⃰ ⃰: p is highly 
significant. 
 
Multiple regression (assessed by 
standardized B coefficients) analysis to find an 
independent predictor for an increase of liver stiffness 
revealed that platelet count is the independent factor 
for increasing liver stiffness measurement by ARFI (B 
= -0.006, P = 0.048, significant). There was no any 
significant impact of sex or past history of 
Schistosomiasis on liver stiffness measurements (p 
values were: 0.812 and 0.262 respectively, 
insignificant).  
As regards diagnostic accuracy of ARFI 
technique for liver fibrosis detection, we found that 
shear wave velocity can predict F1 at a cut-off value 
1.22 with 67.6% sensitivity and 75% specificity. A cut 
off value1.32 can predict F2 with 75.0 % sensitivity 
and 90.9 % specificity. A cut-off value 1.44 can predict 
F3 with 96.6% sensitivity and 75% specificity. A cut-off 
value 1.8 can predict F4 with 95.7 % sensitivity and 
100% specificity Table 4 and Fig. 4.  
Table 4: Diagnostic performance of ARFI for liver fibrosis 
diagnosis 
 Shear wave velocity 
m/sec 
Cut off value 
AUR Specificity Sensitivity PPV NPV 
F1 1.22 0.639 75% 67.6% 87.50% 60% 
F2 1.32 0.727 90.9 % 75.0 % 90.9 % 75.0 % 
F3 1.44 0.905 75% 96.6% 96.6% 100% 
F4 1.80 0.989 100% 95.7 % 100% 40% 
AUR: area under curve; PPV: positive predictive value; NPV: negative predictive value. 
 
 
Discussion 
 
Early detection of liver fibrosis is very 
important for proper management of chronic liver 
disease patients, especially in our country. To best of 
our knowledge, this study is the first to detect 
accuracy of ARFI as a non-invasive diagnostic 
technique for liver fibrosis among Egyptian patients. 
All enrolled patients were recruited from Agouza Liver 
Center and outpatient’s clinics of National Research 
Center., these patients come from all governorates of 
Egypt seeking medical advice, thus, we think our 
patient's sample represents patients all over the 
country.  
a) 
 
b) 
 
Figure 4: a) ROC curve for diagnosis of liver fibrosis grade 1 by 
ARFI; b) ROC curve for diagnosis of liver fibrosis grade 2 by ARFI 
 
In the current study, we found that ARFI 
elastography can predict different grades of liver 
fibrosis with reasonable sensitivity and specificity. The 
area under the curve was highest for F ≥ 3 and F = 4. 
Thus, the ability to diagnose late fibrosis (F ≥ 3) and 
cirrhosis (F = 4) is higher than that for early fibrosis (F 
≥ 1 and F ≥ 2). Our findings agree with previous 
studies, a meta-analysis of nine studies [15-23] 
showed that ARFI imaging had excellent diagnostic 
accuracy for the staging of liver fibrosis in various 
chronic liver diseases; compared with liver biopsy, 
ARFI was highly accurate in the diagnosis of fibrosis 
stage F ≥ 3 (AUROC = 0.91) and for the diagnosis of 
liver cirrhosis (AUROC = 0.93) [24]. Moreover, an 
international multicenter study of 911 HCV mono-
infected patients found that ARFI was highly accurate 
in the diagnosis of fibrosis stage F ≥ 3 
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(AUROC = 0.83) [25]. 
 Spore and his colleagues reported that in 
daily practice, seldom more than one noninvasive 
electrographic method for liver fibrosis assessment is 
available at any center. Thus, the hepatologist must 
use the most cost-effective one. According to their 
results, ARFI elastography could be this method as it 
has a significantly higher rate of reliable liver stiffness 
(LS) measurements, compared with transient 
elastography (TE). Also, as previously noted, most of 
the published studies [26-31] have reported similar 
accuracy for ARFI and TE in the evaluation of liver 
fibrosis. ARFI has another advantage compared with 
TE: It can be integrated into a standard ultrasound 
system (which can also be used for standard 
ultrasound evaluation, contrast-enhanced ultrasound, 
and/or Doppler examinations). 
According to Rizzo and his colleagues [32], 
their study included 139 patients with chronic HCV 
infection, ARFI was more accurate than TE for the 
noninvasive staging of both significant (≥ F2) 
(AUROC: 0.86 vs. 0.78, P = 0.024) and severe (F3-
F4) fibrosis (AUROC: 0.94 vs. 0.83, P = 0.02). 
Importantly, no cases of invalid measurements were 
recorded vs. 6.5% of unreliable results in patients 
undergoing TE (P = 0.029). Moreover, in contrast to 
TE, liver steatosis does not seem to influence ARFI 
[33]. Another advantage is that it can be easily 
incorporated into a modified U/S machine. Further 
validation including inter- and intra-operator 
reproducibility is required before ARFI can be used in 
routine clinical practice. 
Lupsor, and his colleagues [34] reported that 
the cut-off values (m/s) for fibrosis stages were: 1.19 
(F ≥ 1), 1.34 (F ≥ 2), 1.61 (F ≥ 3) and 2.00 (F4). The 
study was performed in 112 patients. When they 
compared ARFI and TE, the areas under the receiver 
operating characteristic curves (AUROC) were 0.709 
vs. 0.902, P = 0.006 (F ≥ 1), 0.851 vs. 0.941, P = 
0.022 (F ≥ 2), 0.869 vs. 0.926, P = 0.153 (F ≥ 3) and 
0.911 vs. 0.945, P = 0.331 (F4). Sporea, and his 
colleagues [10] concluded that the cut-off values for 
predicting the stages of fibrosis were 1.19 m/s for F ≥ 
1 (based on Metavir staging system), 1.21 m/s, (F ≥ 
2), 1.58 m/s (F ≥ 3) and 1.82 m/s (F = 4). This was 
conducted in 247 patients with hepatitis C. 
Our findings with that of previous studies 
contribute to confirming the accuracy of ARFI as a 
noninvasive promising device for liver fibrosis and 
cirrhosis. From a practical point of view, management 
of early fibrosis (F1 and F2) is different from that of 
late fibrosis (F3) or cirrhosis (F4).Most of these 
studies reported higher sensitivities and specificities 
for F3 and F4.So that the ability of ARFI can 
discriminate late fibrosis (F3) and cirrhosis (F4) from 
early fibrosis (F1 and F2) increase its feasibility as a 
noninvasive diagnostic tool for liver fibrosis.  
ARFI elastography was properly correlated 
with biochemical markers for hepatitis as it was 
directly correlated to AST; ALT; INR while it was 
inversely correlated to albumin; prothrombin 
concentration and platelets. Moreover, ARFI 
elastography increased gradually with the advance of 
live fibrosis. This is a more added evidence for ARFI 
as a diagnostic technique for liver fibrosis. 
Hepatic fibro genesis is the corner stone of 
progression of any chronic liver disease. So that, we 
think it’s time to pay more efforts in the field of 
detection of liver fibrosis. We search for an accurate; 
easy; cheap and can be used the frequent method to 
help us not only in diagnosing liver fibrosis but we can 
follow up our patients to detect progression or even 
regression of fibrosis especially among patients who 
receive antiviral treatment for chronic viral infection. 
Although Egypt has the highest prevalence of HCV 
infection, we think that with continuous health 
promotion and new antiviral treatments, the incidence 
of chronic HCV infection among Egyptian will be 
decreased in the near future. But there is another big 
health problem that threatens Egyptian livers which 
are a nonalcoholic fatty liver disease (NAFLD). We 
previously searched for NAFLD among some 
Egyptian healthy subjects; we found that NAFLD was 
detected in 47 (65.3%) children and in 52 (62.7%) 
adults [35]. Fatty liver disease patients in our country 
usually consider that NAFLD is a normally associated 
condition with obesity and overweight cases. They do 
not know the progression of NAFLD into nonalcoholic 
steatohepatitis (NASH); liver cirrhosis or even 
hepatocellular carcinoma. These patients cannot 
agree for their liver to be biopsied for pathological 
examination. Thus, use of noninvasive accurately, a 
diagnostic device for liver fibrosis is mandatory for 
patients and doctors. 
For the past 50 years, liver biopsy has been 
considered to be the gold standard for staging of liver 
fibrosis. However, many recent studies clearly 
highlight several crucial drawbacks of liver biopsy, 
including variable accessibility, high cost, sampling 
errors and inaccuracy due to inter-and intra-observer 
variability of pathologic interpretations [36]. In 
addition, there is a small but important risk of liver 
biopsy-associated morbidity and mortality, with pain 
and hypotension as the most frequent complications 
and intra peritoneal bleeding and injury to the biliary 
system as the most serious complications. Studies 
reveal that the risk for hospitalization after liver biopsy 
is 1-5%, the risk for severe complications is 0.57%, 
and mortality rates vary from 0.009% to 0.12% [37]. 
Because of these reasons, some patients may opt to 
forgo liver biopsy and may not know the stage of their 
liver disease with important prognostic implications. 
The liver biopsy is not a golden standard method for 
liver fibrosis any more, but it could be considered the 
best available standard method. The activating validity 
of noninvasive techniques for liver fibrosis detection 
will help us to observe the liver continuously. 
Moreover, paving the way for therapeutic intervention 
 Elhosary et al. Accuracy of Acoustic Radiation Force Impulse (ARFI) in Diagnosis of Liver Fibrosis 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci. 2016 Sep 15; 4(3):374-380.                                                                                                                                                         379 
 
aiming to reverse liver fibrosis or at least stop its 
progression. 
In conclusion, acoustic radiation force impulse 
elastography is a feasible method for assessment of 
liver fibrosis among Egyptian patients with chronic 
HCV infection. 
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